HC Wainwright Issues Positive Forecast for ARQT Earnings

Key Points

• HC Wainwright raised their Q3 2025 earnings per share estimate for Arcutis Biotherapeutics from ($0.16) to ($0.10), signaling a positive outlook for the company.
• Arcutis Biotherapeutics recently reported Q2 earnings of ($0.13) per share, exceeding analysts' expectations and achieving revenue of $81.50 million.
• The company has received a majority of buy ratings from analysts, with a consensus price target of $19.80, reflecting investor confidence in its future performance.

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) - Research analysts at HC Wainwright raised their Q3 2025 earnings estimates for shares of Arcutis Biotherapeutics in a research note issued on Thursday, August 7th. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings per share of ($0.10) for the quarter, up from their prior forecast of ($0.16). The consensus estimate for Arcutis Biotherapeutics' current full-year earnings is ($1.33) per share. HC Wainwright also issued estimates for Arcutis Biotherapeutics' Q4 2025 earnings at ($0.06) EPS, FY2025 earnings at ($0.49) EPS, Q1 2026 earnings at ($0.10) EPS, Q2 2026 earnings at ($0.05) EPS and FY2026 earnings at $0.08 EPS.

Several other research analysts have also recently issued reports on the stock. Needham & Company LLC lifted their target price on shares of Arcutis Biotherapeutics from $20.00 to $22.00 and gave the stock a "buy" rating in a report on Thursday, August 7th. Cowen reaffirmed a "buy" rating on shares of Arcutis Biotherapeutics in a report on Thursday, August 7th. Wall Street Zen raised shares of Arcutis Biotherapeutics from a "hold" rating to a "buy" rating in a report on Saturday, August 9th. Finally, The Goldman Sachs Group started coverage on shares of Arcutis Biotherapeutics in a report on Friday, July 25th. They issued a "neutral" rating and a $18.00 target price for the company. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, Arcutis Biotherapeutics presently has an average rating of "Moderate Buy" and an average price target of $19.80.

Arcutis Biotherapeutics Stock Up 1.5%

Arcutis Biotherapeutics stock traded up $0.23 during trading hours on Monday, hitting $15.86. The stock had a trading volume of 467,936 shares, compared to its average volume of 2,140,883. The company has a quick ratio of 3.04, a current ratio of 3.20 and a debt-to-equity ratio of 0.77. The stock has a market capitalization of $1.90 billion, a P/E ratio of -21.15 and a beta of 1.84. Arcutis Biotherapeutics has a 12-month low of $8.03 and a 12-month high of $17.75. The stock's 50-day moving average price is $14.38 and its 200-day moving average price is $14.17.

Arcutis Biotherapeutics (NASDAQ:ARQT - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported ($0.13) earnings per share for the quarter, beating analysts' consensus estimates of ($0.18) by $0.05. Arcutis Biotherapeutics had a negative net margin of 35.40% and a negative return on equity of 62.62%. The firm had revenue of $81.50 million for the quarter, compared to analyst estimates of $72.70 million.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Point72 Asset Management L.P. raised its holdings in Arcutis Biotherapeutics by 617.5% during the fourth quarter. Point72 Asset Management L.P. now owns 1,753,522 shares of the company's stock worth $24,427,000 after purchasing an additional 1,509,136 shares in the last quarter. Paradigm Biocapital Advisors LP purchased a new position in Arcutis Biotherapeutics in the 1st quarter valued at $22,918,000. Cercano Management LLC acquired a new stake in Arcutis Biotherapeutics in the fourth quarter valued at $17,487,000. Millennium Management LLC lifted its holdings in Arcutis Biotherapeutics by 101.3% in the fourth quarter. Millennium Management LLC now owns 2,310,163 shares of the company's stock valued at $32,181,000 after acquiring an additional 1,162,690 shares during the period. Finally, Driehaus Capital Management LLC acquired a new position in shares of Arcutis Biotherapeutics during the 4th quarter worth $15,278,000.

Insider Activity at Arcutis Biotherapeutics

In related news, insider Patrick Burnett sold 23,000 shares of Arcutis Biotherapeutics stock in a transaction on Thursday, July 10th. The shares were sold at an average price of $15.05, for a total value of $346,150.00. Following the sale, the insider owned 115,468 shares of the company's stock, valued at approximately $1,737,793.40. This trade represents a 16.61% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Todd Watanabe sold 11,547 shares of Arcutis Biotherapeutics stock in a transaction on Monday, August 4th. The stock was sold at an average price of $14.33, for a total transaction of $165,468.51. Following the sale, the insider directly owned 901,569 shares in the company, valued at approximately $12,919,483.77. This trade represents a 1.26% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders bought 7,434 shares of company stock worth $99,277 and sold 82,575 shares worth $1,190,000. 9.40% of the stock is owned by corporate insiders.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis.